Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis

Bjoern Neumann, Sarah Foerster, Chao Zhao, Benedetta Bodini, Daniel Salo Reich, Dwight E. Bergles, Ragnhildur Thóra Káradóttir, Catherine Lubetzki, Luke L. Lairson, Bernard Zalc, Bruno Stankoff, Robin J.M. Franklin

Research output: Contribution to journalArticle

Abstract

Regenerative medicines that promote remyelination in multiple sclerosis (MS) are making the transition from laboratory to clinical trials. While animal models provide the experimental flexibility to analyze mechanisms of remyelination, here we discuss the challenges in understanding where and how remyelination occurs in MS.

Original languageEnglish (US)
Pages (from-to)617-619
Number of pages3
JournalCell stem cell
Volume26
Issue number5
DOIs
StatePublished - May 7 2020

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cell Biology

Fingerprint Dive into the research topics of 'Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis'. Together they form a unique fingerprint.

  • Cite this

    Neumann, B., Foerster, S., Zhao, C., Bodini, B., Reich, D. S., Bergles, D. E., Káradóttir, R. T., Lubetzki, C., Lairson, L. L., Zalc, B., Stankoff, B., & Franklin, R. J. M. (2020). Problems and Pitfalls of Identifying Remyelination in Multiple Sclerosis. Cell stem cell, 26(5), 617-619. https://doi.org/10.1016/j.stem.2020.03.017